Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Posters

PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g/g

Learn More
Posters

Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial

Learn More
Posters

Sparsentan in Combination With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN): A Case Series

Learn More
Posters

Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors in Adults With IgA Nephropathy in the Ongoing Phase 2 SPARTACUS Trial

Learn More
Posters

Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT

Learn More
Posters

Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)

Learn More
Posters

Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy 

Learn More
Posters

 Sparsentan in Patients With Prior or Concurrent Immunosuppressive Treatment (IST) for IgA Nephropathy (IgAN): A Case Series 

Learn More
Posters

 Sparsentan in Pediatric Patients With Rare Proteinuric Kidney Disease: Preliminary Findings From the EPPIK Study 

Learn More
Posters

 Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan 

Learn More
Posters FSGS

Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)

Learn More
Posters

Pegtibatinase, an Investigational Enzyme Replacement Therapy, for the Treatment of Classical Homocystinuria (HCU): Design of the HARMONY Phase 3 Study

Learn More
Posters

Latest Results From the COMPOSE®Phase 1/2 Trial for the Treatment of Classical Homocystinuria (HCU) Using Pegtibatinase, a Novel Investigational Enzyme Replacement Therapy

Learn More